Uveal melanoma: The inflammatory microenvironment

Journal of Innate Immunity

Volumn 4, Issue 5-6, 2012, Pages 454-462

  Bronkhorst, Inge H G ^a   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Inflammation; Macrophages; Uveal melanoma

Indexed keywords

CYTOKINE;

CANCER PROGNOSIS; CELL POPULATION; CHROMOSOME LOSS; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; MELANOMA; MYELOID PROGENITOR CELL; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UVEA MELANOMA;

CHROMOSOMES, HUMAN, PAIR 3; HUMANS; INFLAMMATION; IRIS NEOPLASMS; MACROPHAGES; MELANOMA; MONOSOMY; UVEAL NEOPLASMS;

EID: 84866049188     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000334576     Document Type: Review

References (57)

1. Singh AD, Turell ME, Topham AK: Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-1885.
2. Kujala E, Makitie T, Kivela T: Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-4659. (Pubitemid 37315273)
3. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB: Variates of survival in metastatic uveal melanoma. J Clin Oncol 2005; 23: 8076-8080. (Pubitemid 46657410)
4. Damato B, Coupland SE: Managing patients with ocular melanoma: state of the art. Clin Experiment Ophthalmol 2008; 36:589-590.
5. Skalicky SE, Holt PE, Giblin M, Taylor S, Conway RM: Australian Cancer Network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clin Experiment Ophthalmol 2008; 36:646-658.
6. McKenna KC, Chen PW: Influence of immune privilege on ocular tumor development. Ocul Immunol Inf lamm 2010; 18: 80-90.
7. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
8. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL: 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319-326.
9. de la Cruz PO Jr, Specht CS, McLean IW: Lymphocytic infiltration in uveal malignant melanoma. Cancer 1990; 65:112-115. (Pubitemid 20026820)
10. Meecham WJ, Char DH, Kaleta-Michaels S: Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res 1992; 24:20-26.
11. De Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ: HLA expression and tumor-infiltrating immune cells in uve-al melanoma. Graefes Arch Clin Exp Oph-thalmol 1996; 234: 34-42.
12. Durie FH, Campbell AM, Lee WR, Damato BE: Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci 1990; 31: 2106-2110. (Pubitemid 20355824)
13. Lagouros E, Salomao D, Thorland E, Hodge DO, Vile R, Pulido JS: Infiltrative T regulatory cells in enucleated uveal melanomas. Trans Am Ophthalmol Soc 2009; 107:223-228.
14. Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R: Intratumoral fork-head box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-pos-itive uveal melanoma. Cancer 2010; 116: 2224-2233.
15. Makitie T, Summanen P, Tarkkanen A, Kivela T: Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:1414-1421. (Pubitemid 32520728)
16. Anastassiou G, Coupland SE, Stang A, Boe-loeni R, Schilling H, Bornfeld N: Expression of Fas and Fas ligand in uveal melanoma: biological implication and prognostic value. J Pat hol 2001; 194: 466-472. (Pubitemid 32782672)
17. Schmidt T, Carmeliet P: Blood-vessel formation: bridges that guide and unite. Nature 2010; 465:697-699.
18. Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, Jager MJ: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011; 52:643-650.
19. Laver NV, McLaughlin ME, Duker JS: Ocular melanoma. Arch Pathol Lab Med 2010; 134: 1778-1784.
20. Whelchel JC, Farah SE, McLean IW, Burnier MN: Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 1993; 34: 2603-2606. (Pubitemid 23206493)
21. Maat W, Ly LV, Jordanova ES, Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ: Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49:505-510.
22. Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, Luyten GP, de Klein A: Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci 2005; 46: 2253-2257. (Pubitemid 43119466)
23. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008; 454: 436-444.
24. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M: Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63: 2578-2584. (Pubitemid 36608917)
25. Onken MD, Worley LA, Ehlers JP, Harbour JW: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64: 7205-7209. (Pubitemid 39372052)
26. Singh AD, Sisley K, Xu Y, Li J, Faber P, Plum-mer SJ, Mudhar HS, Rennie IG, Kessler PM, Casey G, Williams BG: Reduced expression of autotaxin predicts survival in uveal melanoma. Br J Ophtha lmol 2007; 91: 1385-1392. (Pubitemid 47492881)
27. Makitie T, Summanen P, Tarkkanen A, Kive-la T: Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999; 40: 2471-2480. (Pubitemid 29455473)
28. Ly LV, Baghat A, Versluis M, Jordanova ES, Luyten GP, van Rooijen N, van Hall T, van der Velden PA, Jager MJ: In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 2010; 185: 3481-3488.
29. Esser P, Grisanti S, Bartz-Schmidt K: TGF-beta in uveal melanoma. Microsc Res Tech 2001; 52: 396-400.
30. McKenna KC, Kapp JA: Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J Immunol 2006; 177:1599-1608. (Pubitemid 44092495)
31. Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11:889-896.
32. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG: Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res 1998; 17: 165-173. (Pubitemid 28073782)
33. Polak ME, Borthwick NJ, Johnson P, Hungerford JL, Higgins B, Di Palma S, Jager MJ, Cree IA: Presence and phenotype of dendritic cells in uveal melanoma. Br J Ophthalmol 2007; 91:971-976. (Pubitemid 47013116)
34. Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, Luyten GP, Jager MJ: Inflammatory cytokines in eyes with uveal melanoma and relation with macro-phage infiltration. Invest Ophthalmol Vis Sci 2010; 51: 5445-5451.
35. He YG, Mayhew E, Mellon J, Niederkorn JY: Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. Invest Ophthalmol Vis Sci 2004; 45: 4240-4246. (Pubitemid 39564645)
36. Callejo SA, Marshall JC, Cools-Lartigue J, Saraiva VS, Burnier MN Jr: Macrophage-derived soluble factor enhances melanoma inhibitory activity expression by uveal melanoma cells in vitro. Melanoma Res 2004; 14: 91-95. (Pubitemid 38535087)
37. Gottfried E, Kreutz M, Mackensen A: Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 2008; 19: 65-77. (Pubitemid 351200062)
38. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R: Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999; 9: 445-450. (Pubitemid 29494109)
39. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM: EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 1801-1806. (Pubitemid 36520264)
40. Repp AC, Mayhew ES, Apte S, Niederkorn JY: Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol 2000; 165: 710-715. (Pubitemid 30484736)
41. Filer RS, Song JC, Char DH, Kaleta-Michaels S: Uveal melanoma cytokines (in German). Klin Monbl Augenheilkd 1993; 202:174-179.
42. Niederkorn JY: Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res 2009; 28:329-347.
43. Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY: PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci 2008; 49: 2518-2525.
44. Chen PW, Mellon JK, Mayhew E, Wang S, He YG, Hogan N, Niederkorn JY: Uveal melanoma expression of indoleamine 2,3-deoxy-genase: establishment of an immune privileged environment by tryptophan depletion. Exp Eye Res 2007; 85: 617-625. (Pubitemid 47633574)
45. Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr: Secretion of in-terleukin-6 and prostaglandin E2 during uveal melanoma-monocyte in vitro interactions. Exp Eye Res 2004; 79: 451-454. (Pubitemid 39232115)
46. Cools-Lartigue J, Marshall JC, Caissie AL, Saraiva VS, Burnier MN Jr: Secretion of he-patocyte growth factor and vascular endo-thelial growth factor during uveal melano-ma-monocyte in vitro interactions. Melanoma Res 2005; 15:141-145. (Pubitemid 40839460)
47. Marshall JC, Caissie AL, Cruess SR, Cools-Lartigue J, Burnier MN Jr: The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. J Carcinog 2007; 6:17.
48. Triozzi PL, Aldrich W, Singh A: Effects of in-terleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest Ophthalmol Vis Sci 2011; 52:5529-5535.
49. Papastefanou VP, Cohen VM: Uveal melanoma. J Skin Cancer 2011; 2011:1-13.
50. Schilling H, Sehu KW, Lee WR: A histologic study (including DNA quantification and Ki-67 labeling index) in uveal melanomas after brachytherapy with ruthenium plaques. Invest Ophthalmol Vis Sci 1997; 38:2081-2092. (Pubitemid 27407527)
51. Messmer E, Bornfeld N, Foerster M, Schilling H, Wessing A: Histopathologic findings in eyes treated with a ruthenium plaque for uveal melanoma. Graefes Arch Clin Exp Ophthalmol 1992; 230: 391-396.
52. Schurmans LR, Blom DJ, De Waard-Siebinga I, Keunen JE, Prause JU, Jager MJ: Effects of transpupillary thermotherapy on immuno-logical parameters and apoptosis in a case of primary uveal melanoma. Melanoma Res 1999; 9: 297-302. (Pubitemid 29461148)
53. Dennaoui J, Bronkhorst IH, Ly LV, de Wolff-Rouendaal D, Keunen JE, Schalij-Delfos NE, Jager MJ: Changes in immunological markers and influx of macrophages following trans-scleral thermotherapy of uveal melanoma. Acta Ophthalmol 2011; 89:268-273.
54. Young LH, Gragoudas ES: Macular uveal mela noma t reated with proton bea mirradiation. 10-year follow-up observation with his-topathologic correlation. Retina 1994; 14: 43-46. (Pubitemid 24119502)
55. Toivonen P, Makitie T, Kujala E, Kivela T: Macrophages and microcirculation in regressed and partially regressed irradiated choroidal and ciliary body melanomas. Curr Eye Res 2003; 27: 237-245. (Pubitemid 37315483)
56. Toivonen P, Kivelä T: Infiltrating mac-rophages in extratumoural tissues after brachytherapy of uveal melanoma. Acta Ophthalmol 2010, E-pub ahead of print.
57. Toivonen P, Kivelä T: Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology 2006; 113:865-873.